SlideShare une entreprise Scribd logo
1  sur  52
HEMOLYTIC UREMIC
SYNDROME
PRESENTER: DR VIJITHA A S
• First described by Gasser et al in 1955.
• Hemolytic uremic syndrome (HUS) is a leading cause of acute kidney
injury in children. It is a triad of
Micro-angiopathic hemolytic
anemia (MAHA)
Acute kidney injury (acute renal
failure)
Thrombocytopenia
EPIDEMIOLOLOGY
• Epidemiology of HUS in India differs from that in developed countries.
• Worldwide, the chief cause of HUS is Shiga toxin producing E. coli
(STECHUS), which is seen in 80% patients.
• In India, infection with S. dysenteriae is the commonest cause, recent
times prevalence declined significantly.
CLASSIFICATION
Classification of hemolytic uremic syndrome (HUS)
Shiga toxin-associated HUS Shiga toxin-producing Escherichia coli, Shigella dysenteriae type 1,
- Citrobacter, Campylobacter
Pneumococcal HUS Invasive infection with neuraminidase-producing Streptococcus pneumoniae
Infection-associated HUS −Triggered by influenza A, human immunodeficiency virus,
−cytomegalovirus, Epstein-Barr virus, parvovirus B19, Coxsackie virus,
−echovirus, varicella virus, hepatitis A, B, and C, Salmonella typhi,
−Bartonella, leptospira, malaria, dengue, and rickettsia
Type
Secondary HUS Systemic lupus erythematosus; antiphospholipid antibody syndrome
Hematopoietic stem cell or solid organ transplant
Malignancy
Malignant hypertension
Drugs: quinine, mitomycin, ticlopidine, clopidogrel, calcineurin
inhibitors, sirolimus, oral contraceptives, bevacizumab
Defective cobalamin
metabolism
Homozygous or compound heterozygous mutation in MMACHC
Atypical HUS • Factor H deficiency (mutations, autoantibodies)
• Factor I deficiency (mutations)
• Factor B (gain-of-function mutations)
• Membrane cofactor (MCP) deficiency (mutations)
• C3 deficiency (mutations, autoantibodies)
• Thrombomodulin deficiency (mutations)
• Anti–complement factor H antibody
• Unknown
Two main categories of HUS
Stx-HUS: (tHUS)
D+ HUS
D- HUS
Non-StxHUS: (aHUS)
Sporadic
Familial
• Shiga-like toxin associated HUS (Stx-HUS)
• Non-shiga-like toxin associated HUS (non-Stx-HUS)
Typical/Diarrhea associated/Shiga Toxin
associated HUS
• Enterohaemorrhagic E. coli (EHEC) infection (serotype O157:H7 )
• Shigella dysenteriae type 1 infection
• Rarely, HUS can occur with E. coli urinary tract infection.
• Shigatoxins (also called verotoxins [VT] or shiga-like toxins [ST]) are composed of two subunits:
• a larger A subunit - that inhibits protein synthesis by blocking elongation factor-1 dependent binding
of aminoacyl-tRNA to ribosomes
• Five B subunits- mediate binding of the toxin with a membrane glycolipid, globotriaosylceramide or
Gb3
• Gb3 is the cell surface receptor for shigatoxin found in kidney, brain liver, pancreas and heart.
• S. dysenteriae 1 is the most potent toxin producer, S. dysenteriae invades the bowel wall, thus
allowing larger quantities of the toxin to enter the circulation
• Shigatoxin 1 (ST-1) produced by E. coli is identical to the shigella shigatoxin, differing by only one
amino acid in the A subunit
Risk factors for occurrence of HUS are:
young age (< 5 years)
> 3 days of diarrhea,
blood in stools
high leukocyte count (> 15,000/μl)
Source of infection
• feco-oral transmission.
• Milk and animal products (incompletely cooked)
• Veges, salads, drinking water contaminated by bacteria shed in
animal wastes.
Pathogenesis
• Shiga-like toxin affects endothelial cells with Gb3 and initiates intravascular thrombo-
genesis.
• After entering the circulation via the gastrointestinal mucosa, the toxin preferentially
localizes to the kidneys, inhibiting protein synthesis and eventually leading to cell necrosis or
apoptosis.
• Endothelial cell damage subsequently potentiates renal microvascular thrombosis by
promoting activation of the blood coagulation cascade.
• Platelet aggregation results in a consumptive thrombocytopenia.
• Microangiopathic hemolytic anemia results from mechanical damage to red blood cells
circulating through partially occluded microcirculation.
Histopathological hallmark of HUS
• Thrombotic microangiopathy (TMA) Characterized by:
− Capillary endothelial damage.
− Microvascular formation of platelet/fibrin plugs.
− This induces tissue ischemia
− Damage to erythrocytes
− Consumptive thrombocytopenia.
Pneumococcal HUS
• 5% of all HUS
• 38-43% non-diarrheal HUS are associated with invasive Streptococcus pneumoniae infection
• patients, usually younger than 2 years, with sepsis, pneumonia or meningitis
- positive direct Coombs’ test without features of DIC.
• Renal endothelial cells, erythrocytes and platelets have a structure on their surface called Thomsen-
Friedenreich antigen (TAg). This is normally obscured by neuraminic acid.
• Pneumococci containing the enzyme-neuraminidase, which cleave this neuraminic acid from the cell surface
thus exposing the TAg .
• This leads to antigen-antibody binding, activation of an immune cascade, with resultant, glomerular
endothelial cell damage, hemolytic anemia, platelet aggregation and consumption, and a fall in GFR.
• This TAg is also present on hepatocytes, and hepatic dysfunction may coexist.
HUS DUE TO COMPLEMENT ABNORMALITIES
• The majority of non-infection related HUS in children is due to complement dysregulation.
• Complement gene mutations are found in 30-50% patients with aHUS.
Includes abnormalities of
Factor H (FH) gene, (14-33%)
membrane co-factor protein (MCP) gene (10-15%)
Factor I (FI) gene 2-13%.
• These genes code for proteins that inhibit activity of complement C3b.
• Deficiency causes- unregulated amplification of the alternative pathway and deposition of
activated complement on the surface of invading bacteria or damaged self-tissue, such as
apoptosed or inflamed renal endothilial cells.
ADAMTS13 deficiency and HUS/ TTP
• ADAMTS-13 is an enzyme produced by stellate cells in the liver.
• It acts as a von Willebrand factor (VWF) cleaving protease, and degrades
large multimeric forms of VWF by cleaving peptide bonds.
• In the deficiency of this enzyme, ultralarge multimeric form of VWF
(ULVWF) released by stimulated endothelial cells circulate in plasma.
• Circulating platelets spontaneously and preferentially bind to ULVWF strings
(rather than to smaller VWF). Continuing platelet aggregation, ensuing TMA
and embolisation of ULVWF-platelet strings causes tissue ischemia.
ADAMTS-13 deficiency
Familial:
• usually in children.
• rare.
Acquired:
• more common in adults and older children.
• Associated with presence of anti-ADAMTS13 antibodies.
• Manifestation classically of frank TTP (pentad of fever, neurological manifestations,
TMA, severe thrombocytopenia, and relatively less severe renal dysfunction)
Cobalamin deficiency-associated HUS
• Cobalamin deficiency accounts for a small (~ 6–8%) proportion of patients with HUS
• Homozygous or compound heterozygous mutation in MMACHC
• It can present at all ages, ranging from neonates to adults, and does not respond to PEX
• Features include - failure to thrive, feeding difficulties, seizures, abnormal muscle tone, visual
impairment, and developmental delay.
• Megaloblastic anemia is present in 10– 25%.
• two-third patients have extrarenal feature
neurological (44%) or cardiopulmonary (39%) disease and pulmonary hypertension (17%) are
frequent.
CLINICAL FEATURES
shiga Toxin associated HUS
It occurs commonly in children between 1-5 years of age
The commonest clinical presentations
• HUS occurs 5-7 days after the onset of gastroenteritis with fever, vomiting,
abdominal pain, diarrhea or dysentery.
• Following the prodromal illness, the sudden onset of- pallor, weakness, and
lethargy
• Significant dehydration or volume overload
• Renal - Oliguria present in early stages /masked by ongoing diarrhea
- Hematuria and hypertension are common
- Renal insufficiency can be mild to severe oliguric or anuric renal failure.
- life-threatening hyperkalemia(renal failure+severe hemolysis)
- Severe acute kidney injury requiring dialysis develops in about 50% of
patients with STEC-HUS.
- The duration of the dialysis requirement is usually about 2 wk.
• Cardiac - heart failure(Volume overload, hypertension, and severe
anemia )
- Direct cardiac involvement is rare
- pericarditis, myocardial dysfunction, or arrhythmias can
occur without predisposing features of hypertension, volume overload,
or electrolyte abnormalities.
• CNS- mild manifestations - irritability, lethargy, or nonspecific encephalopathic features.
• Severe CNS involvement- ≤ 20% of cases.
- Seizures and significant encephalopathy resulting from focal ischemia secondary to microvascular CNS
thrombosis
• Hypertension encephalopathy and seizures.
• Intestinal complications are variable
- include severe inflammatory colitis, ischemic enteritis, bowel perforation, intussusception, and pancreatitis.
• hematological - petechiae, significant or severe bleeding is rare despite very low platelet counts
CLINICAL FEATURES..
• pneumococci-associated HUS- pt will be ill with pneumonia,
empyema, and bacteremia when they develop HUS
• genetic forms of HUS – insidious, triggered by a variety of illnesses,
including mild, nonspecific gastroenteritis or respiratory tract
infections.
CLINICAL FEATURES..
• Cobalamin deficiency-associated HUS
c/f
• Feeding difficulties, seizures ,abnormal muscle tone, developmental
delay and megaloblastic anemia are common;
• Rarely- HUS have an indolent presentation- with AKI and systemic
hypertension without thrombocytopenia or microangiopathic
hemolysis.
DIAGNOSIS OF HUS
(i) microangiopathic hemolysis characterized by
- anemia -(hemoglobin <10 g/dL)
- fragmented red cells on peripheral smear (schistocytes ≥2%),
- High lactate dehydrogenase >450 IU/l (increased breakdown and turnover of RBC’S)
or - undetectable haptoglobin(binding with released hemoglobin. )
(ii) thrombocytopenia (platelets <150,000/μL)
(iii) AKI- (rise in creatinine by 50% over baseline).
.
HEMOLYTIC UREMIC SYNDROME IN CHILDREN 2022 BY DR VIJITHA
• The degree of leukocytosis -poor outcome
• Reticulocyte levels are high.
• The degree of renal involvement - increase in blood urea, creatinine,
potassium and phosphate.
• liver transaminases, pancreatic enzymes and glucose levels may be
affected.
• Urinalysis reveals- hemoglobinuria, hematuria and proteinuria.
SUSPECTED SHIGA TOXIN ASSOCIATED HUS: DIAGNOSIS
confirmed by positive stool culture and either of the following
(i) Detection of virulence genes on fecal extracts or cultures
(stx1, stx2, and eae gene by PCR)
(ii) Free fecal Shiga toxin (detected on tissue culture or immunoassay)
(iii) The presence of serum IgM antibodies against specific E. coli
lipopolysaccharide -evidence for recent STEC infection
(by ELISA, passive hemagglutination assay)
DIAGNOSIS OF PNEUMOCOCCAL HUS
• positive direct Coombs’ test without features of DIC
• confirmed by either:
(i) S. pneumoniae isolation - bacterial culture
- detection of pneumococcal antigen by PCR or ELISA in appropriate
body fluids (sputum/CSF/blood/pus) or
- positive peanut lectin (Arachis hypogaea) agglutination assay
COBALAMIN DEFICIENCY-ASSOCIATED HUS
• screening for cobalamin C (cblC) deficiency by estimating total
homocysteine levels
• Probable cblC deficiency-related HUS- elevated plasma total
homocysteine level (> 50–100 μM/l by chromatography, immunoassay)
with normal levels of vitamin B12 and folate.
• Confirmed cblC deficiency-related HUS- Homozygous or compound
heterozygous mutation in the MMACHC gene in a patient with probable
cblC deficiency.
Rule-out
• Disseminated intravascular coagulation (DIC) - prolonged prothrombin time or
activated partial thromboplastin time, low fibrinogen, elevated D-dimer and soluble
fibrin monomers.
• Thrombotic thrombocytopenic purpura (TTP) -rare in childhood
-persistent thrombocytopenia (<30,000/μL) and mild/no AKI is suggestive
• Infections that mimic/trigger HUS, e.g., malaria, leptospirosis, dengue, rickettsia
and H1N1 infection should be excluded, if clinically suspected.
• Blood samples should be stored and later processed for ADAMTS13 activity, if
etiology of microangiopathic anemia is unclear.
EVALUATION OF ATYPICAL HUS
Complement C3 - A low C3 level is not specific for aHUS, nor does it
correlate with severity of disease
test for anti-factor H (FH) antibodies – ELIZA
flow cytometry for expression of membrane cofactor protein (MCP, CD46) on
neutrophils
Gene sequencing:of CFH, CFI, CFB, C3, CD46, THBD, and DGKE.
• Blood specimens for C3 and anti-FH antibodies should be drawn prior to
instituting therapy.
Genetic screening is advised
(i) early age of onset
(ii) relapsing course,
(iii) family history of HUS,
(iv) illness that is refractory to therapy with PEX, and
(v) prior to renal transplantation.
RENAL BIOPSY
• Renal biopsy is not essential for diagnosis
• cannot be performed in the acute stage due to thrombocytopenia.
• Indicated - partial forms where the diagnosis is in doubt,
or in recurrent or severe disease,
to confirm the diagnosis before starting aggressive therapies.
The pathognomic finding of TMA is common to all types.
RENAL BIOPSY.
 Thus - predominantly fibrin thrombi are found in glomerular capillaries.
aHUS- the thrombi are made up of a combination of fibrin, platelet and VWF clumps that involve
larger renal and interlobular arterioles, thus causing ischemia and inflammation of larger volumes of
renal parenchyma
- Glomerular capillary wall thickening, occlusion or narrowing of capillary lumens, inflammation and
necrosis of endothelial cells and their detachment from the basement membrane may be observed.
- Tubular epithelial injury, mesangial expansion and mesangiolysis may also occur
• Cortical necrosis is present in severe cases, and indicates a poor outcome
A) Occluded afferent arteriole with ischemic changes in the accompanying glomerulus
B) Glomerulus showing mesangiolysis and ectatic dilatation of glomerular capillaries (silver
methenamine
C) (C) Necrotizing vascular lesions of the afferent and efferent arterioles
D) (D) Fibrin rich thrombus occluding the lumen of a small artery with ischemic changes in adjacent
glomerulus
HEMOLYTIC UREMIC SYNDROME IN CHILDREN 2022 BY DR VIJITHA
DFFERNTIAL DIAGNOSIS
• Acute abdomen
• Acute gastroenteritis
• Appendicitis
• Colitis
• Disseminated intravascular coagulation
• Inflammatory bowel disease
• Lupus
• Thrombotic thrombocytopenia
MANAGEMENT
Supportive Therapy
• In all patients, supportive treatment is primary.
• Close clinical monitoring of :
-Fluid status
-Blood pressure
-Neurological
-Ventilatory parameters
• Blood levels of glucose, electrolytes, creatinine and hemogram need frequent
monitoring
MANAGEMENT..
• Dialysis - early institution- if the patient - significantly oliguric or anuric, with
hyperkalemia.
• The duration of the dialysis requirement is usually about 2 wk.
• Red cell transfusions required because hemolysis can be brisk and recurrent until the
active phase of the disease has resolved.
-In pneumococci associated HUS- administer washed red cells to be given
Platelets should not be administered ( Rapidly consumed by the active coagulation
,worsen the clinical course)
• Anticoagulation, antiplatelet, and fibrinolytic therapies are specifically
contraindicated- increase the risk of serious hemorrhage.
• Antibiotic therapy to clear enteric toxigenic organisms (STEC) can result in
increased toxin release, potentially exacerbating the disease, and therefore is
not recommended.
- Indicated in pneumococcal infection.
• Plasma infusion or plasmapheresis- patients suffering from severe
manifestations of HUS with serious CNS involvement.
• contraindicated in pneumococcal associated HUS -exacerbate the disease
MANAGEMENT- Atypical HUS:
ECULIZUMAB
• Across the developed world, eculizumab, is the standard of care for
patients with aHUS.
• FDA approved for the treatment of atypical HUS
• Eculizumab is an anti-C5 antibody that inhibits complement activation,
a pathway that contributes to active disease in atypical familial HUS.
• recommended to give the meningococcal vaccine prior to giving
eculizumab (if the patient has not been primarily immunized)- risk of
meningococcal disease in patients with defects in terminal
complement components
• eculizumab is expensive and not available in India and developing
countries.
PLASMA EXCHANGE
• In absence of anti-complement therapies, intensive PEX is less than ideal, but the only alternative.
• PEX - (60- 75 mL/kg; fresh frozen plasma as exchange fluid) - appropriate for patients with
suspected aHUS.
• PEX is administered daily until hematological remission and tapered over 4-6 weeks.
- (platelets >100,000/ μL, schistocytes <2%, LDH less than upper limit of normal for 2 consecutive
days)
• Maintenance therapy with plasma infusions is advised every 10-14 days for patients with
mutations in complement genes, especially CFH and CFI.
• Limited benefit of PEX in patients with:
(i) microbiologically confirmed STEC-HUS, without cardiac or
neurological involvement,
(ii) infection-associated HUS or pathogenic variants in CD46 and DGKE.
MANAGEMENT - ANTI-FH ANTIBODY ASSOCIATED AHUS:
• Aim of therapy - anti-FH associated HUS is reduction of titers, PEX are most appropriate to achieve this goal.
• Combination of PEX and immunosuppression was most useful.
• Immunosuppression must not be used without confirming presence of anti-FH antibodies.
• Therapy is initiated with prednisolone 1 mg/kg/day for 4 weeks, then alternate-day followed by tapering over 10-
12 months
• Therapy includes cyclophosphamide (500 mg/m2 intravenously once in 4-weeks) for 5 doses
• About 15- 30% patients relapse; Antibody titers should be sequentially measured, especially in the first 12-24
months of follow up.
• Maintenance therapy with mycophenolate mofetil or azathioprine for 18-24 months, and tapering prednisolone
further reduces the risk of relapses.
HEMOLYTIC UREMIC SYNDROME IN CHILDREN 2022 BY DR VIJITHA
Management - Miscellaneous
• In infants with HUS associated with cobalamin abnormalities:
Treatment with hydroxycobalamin, Oral betaine, Folic acid
• Normalizes the metabolic abnormalities - prevent further episodes.
• In patients with persistent ADAMTS13 antibodies and poor response
to plasma exchange:
• Immunosuppressive therapy with high dose -
steroids/cyclophosphamide/cyclosporin/rituximab
PROGNOSIS
• With early recognition and intensive supportive care, the mortality
rate for diarrhea-associated HUS is < 5% in most major medical
centers.
• Up to half of patients may require dialysis support during the acute
phase of the disease.
• Recovery of platelet counts usually occurs first, followed by renal
recovery about 5 days later, and finally by resolution of anemia.
• Surviving patients, 5% remain dependent on dialysis, and up to 30%
are left with some degree of chronic renal insufficiency.
• The prognosis for HUS not associated with diarrhea is more severe.
• Pneumococci-associated HUS causes increased patient morbidity
(>80% require dialysis), with the mortality rate reported as 20%.
• familial, genetic forms of HUS can be insidiously progressive or
relapsing diseases and have a poor prognosis
THANK YOU
REFERENCES
• Guidelines on Hemolytic Uremic Syndrome by Indian Society of
Pediatric Nephrology
• Hemolytic uremic syndrome in a developing country: Consensus
guidelines Pediatric Nephrology Arvind Bagga/Revised: 6 January
2019
• Bagga text book of paediatric nephrology
• Nelson text book of paediatrics 21st edition

Contenu connexe

Tendances

Urinary Tract Infections in children
 Urinary Tract Infections in children Urinary Tract Infections in children
Urinary Tract Infections in childrenAzad Haleem
 
Immune Thrombocytopenic Purpura
Immune Thrombocytopenic PurpuraImmune Thrombocytopenic Purpura
Immune Thrombocytopenic PurpuraNahar Kamrun
 
approach to short stature
approach to short statureapproach to short stature
approach to short statureRatnakar Vallem
 
Chronic Liver Disease in pediatric: a case presentation and discussion
Chronic Liver Disease in pediatric: a case presentation and discussionChronic Liver Disease in pediatric: a case presentation and discussion
Chronic Liver Disease in pediatric: a case presentation and discussionDr Abdalla M. Gamal
 
Pediatric hypertension
Pediatric hypertensionPediatric hypertension
Pediatric hypertensionTauhid Iqbali
 
Neonatal hypocalcemia
Neonatal hypocalcemiaNeonatal hypocalcemia
Neonatal hypocalcemiaMostafa Galal
 
Pediatric thrombocytopenia
Pediatric thrombocytopeniaPediatric thrombocytopenia
Pediatric thrombocytopeniaMarwa Besar
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic SyndromeCSN Vittal
 
Heart failure in children 2021
Heart failure in children 2021Heart failure in children 2021
Heart failure in children 2021Imran Iqbal
 
Approach to a Neonate with Cyanosis
Approach to a Neonate with CyanosisApproach to a Neonate with Cyanosis
Approach to a Neonate with CyanosisAfnan Shamraiz
 
Rheumatic valvular heart disease pediatrics AG
Rheumatic valvular heart disease pediatrics AGRheumatic valvular heart disease pediatrics AG
Rheumatic valvular heart disease pediatrics AGAkshay Golwalkar
 
Acute glomerulonephritis
Acute glomerulonephritisAcute glomerulonephritis
Acute glomerulonephritisSilah Aysha
 
Acute renal failure in children
Acute renal failure in childrenAcute renal failure in children
Acute renal failure in childrenAbhijeet Deshmukh
 
Focal & segmental glomerulosclerosis
Focal & segmental glomerulosclerosisFocal & segmental glomerulosclerosis
Focal & segmental glomerulosclerosisMohammad Manzoor
 

Tendances (20)

Neonatal Cholestasis
Neonatal CholestasisNeonatal Cholestasis
Neonatal Cholestasis
 
Urinary Tract Infections in children
 Urinary Tract Infections in children Urinary Tract Infections in children
Urinary Tract Infections in children
 
Immune Thrombocytopenic Purpura
Immune Thrombocytopenic PurpuraImmune Thrombocytopenic Purpura
Immune Thrombocytopenic Purpura
 
approach to short stature
approach to short statureapproach to short stature
approach to short stature
 
Chronic Liver Disease in pediatric: a case presentation and discussion
Chronic Liver Disease in pediatric: a case presentation and discussionChronic Liver Disease in pediatric: a case presentation and discussion
Chronic Liver Disease in pediatric: a case presentation and discussion
 
Pediatric hypertension
Pediatric hypertensionPediatric hypertension
Pediatric hypertension
 
Neonatal hypocalcemia
Neonatal hypocalcemiaNeonatal hypocalcemia
Neonatal hypocalcemia
 
Pediatric thrombocytopenia
Pediatric thrombocytopeniaPediatric thrombocytopenia
Pediatric thrombocytopenia
 
Henoch Schönlein Purpura
Henoch Schönlein PurpuraHenoch Schönlein Purpura
Henoch Schönlein Purpura
 
Nephrotic Syndrome
Nephrotic SyndromeNephrotic Syndrome
Nephrotic Syndrome
 
Heart failure in children 2021
Heart failure in children 2021Heart failure in children 2021
Heart failure in children 2021
 
INFECTIVE ENDOCARDITIS IN CHILDREN
INFECTIVE ENDOCARDITIS IN CHILDRENINFECTIVE ENDOCARDITIS IN CHILDREN
INFECTIVE ENDOCARDITIS IN CHILDREN
 
Hemolytic uremic syndrome
Hemolytic uremic syndromeHemolytic uremic syndrome
Hemolytic uremic syndrome
 
Pediatric stroke
Pediatric strokePediatric stroke
Pediatric stroke
 
Approach to a Neonate with Cyanosis
Approach to a Neonate with CyanosisApproach to a Neonate with Cyanosis
Approach to a Neonate with Cyanosis
 
Rheumatic valvular heart disease pediatrics AG
Rheumatic valvular heart disease pediatrics AGRheumatic valvular heart disease pediatrics AG
Rheumatic valvular heart disease pediatrics AG
 
Acute glomerulonephritis
Acute glomerulonephritisAcute glomerulonephritis
Acute glomerulonephritis
 
Acute renal failure in children
Acute renal failure in childrenAcute renal failure in children
Acute renal failure in children
 
Pancreatitis in pediatrics
Pancreatitis in pediatrics Pancreatitis in pediatrics
Pancreatitis in pediatrics
 
Focal & segmental glomerulosclerosis
Focal & segmental glomerulosclerosisFocal & segmental glomerulosclerosis
Focal & segmental glomerulosclerosis
 

Similaire à HEMOLYTIC UREMIC SYNDROME IN CHILDREN 2022 BY DR VIJITHA

Hemolytic uremic syndrome
Hemolytic uremic syndromeHemolytic uremic syndrome
Hemolytic uremic syndromeAhmed Zuhry
 
Platelets and platelets disorderz
Platelets and platelets disorderzPlatelets and platelets disorderz
Platelets and platelets disorderzZahid Khan
 
Sindrome hemolítico urêmica
Sindrome hemolítico urêmicaSindrome hemolítico urêmica
Sindrome hemolítico urêmicaAntonio Souto
 
Streptococal Infection .ppt
Streptococal Infection .pptStreptococal Infection .ppt
Streptococal Infection .pptTusharRajput46
 
INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx1901600146
 
AML ZANN.pptx
AML ZANN.pptxAML ZANN.pptx
AML ZANN.pptxZannChua1
 
Haemolytic Uremic Syndrome
Haemolytic Uremic SyndromeHaemolytic Uremic Syndrome
Haemolytic Uremic Syndromefracpractice
 
Multiple myeloma 06-11-2022.pptx
Multiple myeloma 06-11-2022.pptxMultiple myeloma 06-11-2022.pptx
Multiple myeloma 06-11-2022.pptxmanjujanhavi
 
ITP : idiopathic or immune thrombocytopenic purpure
ITP : idiopathic or immune thrombocytopenic purpure ITP : idiopathic or immune thrombocytopenic purpure
ITP : idiopathic or immune thrombocytopenic purpure KaustubhPachade
 
Liver injury-2.pptx bxjdndannsmxmfmsmmssmzmzm
Liver injury-2.pptx bxjdndannsmxmfmsmmssmzmzmLiver injury-2.pptx bxjdndannsmxmfmsmmssmzmzm
Liver injury-2.pptx bxjdndannsmxmfmsmmssmzmzmepicsoundever
 

Similaire à HEMOLYTIC UREMIC SYNDROME IN CHILDREN 2022 BY DR VIJITHA (20)

Hemolytic uremic syndrome
Hemolytic uremic syndromeHemolytic uremic syndrome
Hemolytic uremic syndrome
 
HUS
HUSHUS
HUS
 
Platelets and platelets disorderz
Platelets and platelets disorderzPlatelets and platelets disorderz
Platelets and platelets disorderz
 
Vasculitis
VasculitisVasculitis
Vasculitis
 
Bleeding disorders
Bleeding disordersBleeding disorders
Bleeding disorders
 
Autoimmunity
AutoimmunityAutoimmunity
Autoimmunity
 
Sindrome hemolítico urêmica
Sindrome hemolítico urêmicaSindrome hemolítico urêmica
Sindrome hemolítico urêmica
 
Streptococal Infection .ppt
Streptococal Infection .pptStreptococal Infection .ppt
Streptococal Infection .ppt
 
Acute leukemias
Acute leukemiasAcute leukemias
Acute leukemias
 
INFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptxINFECTIVE ENDOCARDITIS.pptx
INFECTIVE ENDOCARDITIS.pptx
 
Medicine 5th year, 3rd lecture (Dr. Abdulla Sharief)
Medicine 5th year, 3rd lecture (Dr. Abdulla Sharief)Medicine 5th year, 3rd lecture (Dr. Abdulla Sharief)
Medicine 5th year, 3rd lecture (Dr. Abdulla Sharief)
 
AML ZANN.pptx
AML ZANN.pptxAML ZANN.pptx
AML ZANN.pptx
 
Hematuria.docx
Hematuria.docxHematuria.docx
Hematuria.docx
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Haemolytic Uremic Syndrome
Haemolytic Uremic SyndromeHaemolytic Uremic Syndrome
Haemolytic Uremic Syndrome
 
HUS discussion.pptx
HUS discussion.pptxHUS discussion.pptx
HUS discussion.pptx
 
Leukemia.pptx
Leukemia.pptxLeukemia.pptx
Leukemia.pptx
 
Multiple myeloma 06-11-2022.pptx
Multiple myeloma 06-11-2022.pptxMultiple myeloma 06-11-2022.pptx
Multiple myeloma 06-11-2022.pptx
 
ITP : idiopathic or immune thrombocytopenic purpure
ITP : idiopathic or immune thrombocytopenic purpure ITP : idiopathic or immune thrombocytopenic purpure
ITP : idiopathic or immune thrombocytopenic purpure
 
Liver injury-2.pptx bxjdndannsmxmfmsmmssmzmzm
Liver injury-2.pptx bxjdndannsmxmfmsmmssmzmzmLiver injury-2.pptx bxjdndannsmxmfmsmmssmzmzm
Liver injury-2.pptx bxjdndannsmxmfmsmmssmzmzm
 

Plus de Vijitha A S

Functional constipation in children by dr vijitha
Functional constipation in children by dr vijitha Functional constipation in children by dr vijitha
Functional constipation in children by dr vijitha Vijitha A S
 
UTI in children BY DR VIJITHA
UTI in children BY DR VIJITHAUTI in children BY DR VIJITHA
UTI in children BY DR VIJITHAVijitha A S
 
ASCITIS IN CHILDREN BY DR VIJITHA
ASCITIS IN CHILDREN BY DR VIJITHAASCITIS IN CHILDREN BY DR VIJITHA
ASCITIS IN CHILDREN BY DR VIJITHAVijitha A S
 
Gastroesophageal reflux disease in children.Indian Society of Pediatric Gast...
Gastroesophageal reflux disease  in children.Indian Society of Pediatric Gast...Gastroesophageal reflux disease  in children.Indian Society of Pediatric Gast...
Gastroesophageal reflux disease in children.Indian Society of Pediatric Gast...Vijitha A S
 
Hyperkalemia&amp;hypokalemia by dr vijitha
Hyperkalemia&amp;hypokalemia by dr vijithaHyperkalemia&amp;hypokalemia by dr vijitha
Hyperkalemia&amp;hypokalemia by dr vijithaVijitha A S
 
Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...
Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...
Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...Vijitha A S
 
Neonatal sepsis by Dr vijitha
Neonatal sepsis by Dr vijitha Neonatal sepsis by Dr vijitha
Neonatal sepsis by Dr vijitha Vijitha A S
 
Cerebral palsy by Dr vijitha
Cerebral palsy by Dr vijithaCerebral palsy by Dr vijitha
Cerebral palsy by Dr vijithaVijitha A S
 
Neonatal hypoglycemia and hyperglycemia Dr vijitha AS
Neonatal hypoglycemia and hyperglycemia Dr vijitha ASNeonatal hypoglycemia and hyperglycemia Dr vijitha AS
Neonatal hypoglycemia and hyperglycemia Dr vijitha ASVijitha A S
 

Plus de Vijitha A S (9)

Functional constipation in children by dr vijitha
Functional constipation in children by dr vijitha Functional constipation in children by dr vijitha
Functional constipation in children by dr vijitha
 
UTI in children BY DR VIJITHA
UTI in children BY DR VIJITHAUTI in children BY DR VIJITHA
UTI in children BY DR VIJITHA
 
ASCITIS IN CHILDREN BY DR VIJITHA
ASCITIS IN CHILDREN BY DR VIJITHAASCITIS IN CHILDREN BY DR VIJITHA
ASCITIS IN CHILDREN BY DR VIJITHA
 
Gastroesophageal reflux disease in children.Indian Society of Pediatric Gast...
Gastroesophageal reflux disease  in children.Indian Society of Pediatric Gast...Gastroesophageal reflux disease  in children.Indian Society of Pediatric Gast...
Gastroesophageal reflux disease in children.Indian Society of Pediatric Gast...
 
Hyperkalemia&amp;hypokalemia by dr vijitha
Hyperkalemia&amp;hypokalemia by dr vijithaHyperkalemia&amp;hypokalemia by dr vijitha
Hyperkalemia&amp;hypokalemia by dr vijitha
 
Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...
Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...
Hemophagocytic lymphohistiocytosis (hlh), Langerhans cell histiocytosis dr vi...
 
Neonatal sepsis by Dr vijitha
Neonatal sepsis by Dr vijitha Neonatal sepsis by Dr vijitha
Neonatal sepsis by Dr vijitha
 
Cerebral palsy by Dr vijitha
Cerebral palsy by Dr vijithaCerebral palsy by Dr vijitha
Cerebral palsy by Dr vijitha
 
Neonatal hypoglycemia and hyperglycemia Dr vijitha AS
Neonatal hypoglycemia and hyperglycemia Dr vijitha ASNeonatal hypoglycemia and hyperglycemia Dr vijitha AS
Neonatal hypoglycemia and hyperglycemia Dr vijitha AS
 

Dernier

historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 

Dernier (20)

historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 

HEMOLYTIC UREMIC SYNDROME IN CHILDREN 2022 BY DR VIJITHA

  • 2. • First described by Gasser et al in 1955. • Hemolytic uremic syndrome (HUS) is a leading cause of acute kidney injury in children. It is a triad of Micro-angiopathic hemolytic anemia (MAHA) Acute kidney injury (acute renal failure) Thrombocytopenia
  • 3. EPIDEMIOLOLOGY • Epidemiology of HUS in India differs from that in developed countries. • Worldwide, the chief cause of HUS is Shiga toxin producing E. coli (STECHUS), which is seen in 80% patients. • In India, infection with S. dysenteriae is the commonest cause, recent times prevalence declined significantly.
  • 4. CLASSIFICATION Classification of hemolytic uremic syndrome (HUS) Shiga toxin-associated HUS Shiga toxin-producing Escherichia coli, Shigella dysenteriae type 1, - Citrobacter, Campylobacter Pneumococcal HUS Invasive infection with neuraminidase-producing Streptococcus pneumoniae Infection-associated HUS −Triggered by influenza A, human immunodeficiency virus, −cytomegalovirus, Epstein-Barr virus, parvovirus B19, Coxsackie virus, −echovirus, varicella virus, hepatitis A, B, and C, Salmonella typhi, −Bartonella, leptospira, malaria, dengue, and rickettsia
  • 5. Type Secondary HUS Systemic lupus erythematosus; antiphospholipid antibody syndrome Hematopoietic stem cell or solid organ transplant Malignancy Malignant hypertension Drugs: quinine, mitomycin, ticlopidine, clopidogrel, calcineurin inhibitors, sirolimus, oral contraceptives, bevacizumab Defective cobalamin metabolism Homozygous or compound heterozygous mutation in MMACHC Atypical HUS • Factor H deficiency (mutations, autoantibodies) • Factor I deficiency (mutations) • Factor B (gain-of-function mutations) • Membrane cofactor (MCP) deficiency (mutations) • C3 deficiency (mutations, autoantibodies) • Thrombomodulin deficiency (mutations) • Anti–complement factor H antibody • Unknown
  • 6. Two main categories of HUS Stx-HUS: (tHUS) D+ HUS D- HUS Non-StxHUS: (aHUS) Sporadic Familial • Shiga-like toxin associated HUS (Stx-HUS) • Non-shiga-like toxin associated HUS (non-Stx-HUS)
  • 7. Typical/Diarrhea associated/Shiga Toxin associated HUS • Enterohaemorrhagic E. coli (EHEC) infection (serotype O157:H7 ) • Shigella dysenteriae type 1 infection • Rarely, HUS can occur with E. coli urinary tract infection.
  • 8. • Shigatoxins (also called verotoxins [VT] or shiga-like toxins [ST]) are composed of two subunits: • a larger A subunit - that inhibits protein synthesis by blocking elongation factor-1 dependent binding of aminoacyl-tRNA to ribosomes • Five B subunits- mediate binding of the toxin with a membrane glycolipid, globotriaosylceramide or Gb3 • Gb3 is the cell surface receptor for shigatoxin found in kidney, brain liver, pancreas and heart. • S. dysenteriae 1 is the most potent toxin producer, S. dysenteriae invades the bowel wall, thus allowing larger quantities of the toxin to enter the circulation • Shigatoxin 1 (ST-1) produced by E. coli is identical to the shigella shigatoxin, differing by only one amino acid in the A subunit
  • 9. Risk factors for occurrence of HUS are: young age (< 5 years) > 3 days of diarrhea, blood in stools high leukocyte count (> 15,000/μl)
  • 10. Source of infection • feco-oral transmission. • Milk and animal products (incompletely cooked) • Veges, salads, drinking water contaminated by bacteria shed in animal wastes.
  • 11. Pathogenesis • Shiga-like toxin affects endothelial cells with Gb3 and initiates intravascular thrombo- genesis. • After entering the circulation via the gastrointestinal mucosa, the toxin preferentially localizes to the kidneys, inhibiting protein synthesis and eventually leading to cell necrosis or apoptosis. • Endothelial cell damage subsequently potentiates renal microvascular thrombosis by promoting activation of the blood coagulation cascade. • Platelet aggregation results in a consumptive thrombocytopenia. • Microangiopathic hemolytic anemia results from mechanical damage to red blood cells circulating through partially occluded microcirculation.
  • 12. Histopathological hallmark of HUS • Thrombotic microangiopathy (TMA) Characterized by: − Capillary endothelial damage. − Microvascular formation of platelet/fibrin plugs. − This induces tissue ischemia − Damage to erythrocytes − Consumptive thrombocytopenia.
  • 13. Pneumococcal HUS • 5% of all HUS • 38-43% non-diarrheal HUS are associated with invasive Streptococcus pneumoniae infection • patients, usually younger than 2 years, with sepsis, pneumonia or meningitis - positive direct Coombs’ test without features of DIC. • Renal endothelial cells, erythrocytes and platelets have a structure on their surface called Thomsen- Friedenreich antigen (TAg). This is normally obscured by neuraminic acid. • Pneumococci containing the enzyme-neuraminidase, which cleave this neuraminic acid from the cell surface thus exposing the TAg . • This leads to antigen-antibody binding, activation of an immune cascade, with resultant, glomerular endothelial cell damage, hemolytic anemia, platelet aggregation and consumption, and a fall in GFR. • This TAg is also present on hepatocytes, and hepatic dysfunction may coexist.
  • 14. HUS DUE TO COMPLEMENT ABNORMALITIES • The majority of non-infection related HUS in children is due to complement dysregulation. • Complement gene mutations are found in 30-50% patients with aHUS. Includes abnormalities of Factor H (FH) gene, (14-33%) membrane co-factor protein (MCP) gene (10-15%) Factor I (FI) gene 2-13%. • These genes code for proteins that inhibit activity of complement C3b. • Deficiency causes- unregulated amplification of the alternative pathway and deposition of activated complement on the surface of invading bacteria or damaged self-tissue, such as apoptosed or inflamed renal endothilial cells.
  • 15. ADAMTS13 deficiency and HUS/ TTP • ADAMTS-13 is an enzyme produced by stellate cells in the liver. • It acts as a von Willebrand factor (VWF) cleaving protease, and degrades large multimeric forms of VWF by cleaving peptide bonds. • In the deficiency of this enzyme, ultralarge multimeric form of VWF (ULVWF) released by stimulated endothelial cells circulate in plasma. • Circulating platelets spontaneously and preferentially bind to ULVWF strings (rather than to smaller VWF). Continuing platelet aggregation, ensuing TMA and embolisation of ULVWF-platelet strings causes tissue ischemia.
  • 16. ADAMTS-13 deficiency Familial: • usually in children. • rare. Acquired: • more common in adults and older children. • Associated with presence of anti-ADAMTS13 antibodies. • Manifestation classically of frank TTP (pentad of fever, neurological manifestations, TMA, severe thrombocytopenia, and relatively less severe renal dysfunction)
  • 17. Cobalamin deficiency-associated HUS • Cobalamin deficiency accounts for a small (~ 6–8%) proportion of patients with HUS • Homozygous or compound heterozygous mutation in MMACHC • It can present at all ages, ranging from neonates to adults, and does not respond to PEX • Features include - failure to thrive, feeding difficulties, seizures, abnormal muscle tone, visual impairment, and developmental delay. • Megaloblastic anemia is present in 10– 25%. • two-third patients have extrarenal feature neurological (44%) or cardiopulmonary (39%) disease and pulmonary hypertension (17%) are frequent.
  • 18. CLINICAL FEATURES shiga Toxin associated HUS It occurs commonly in children between 1-5 years of age The commonest clinical presentations • HUS occurs 5-7 days after the onset of gastroenteritis with fever, vomiting, abdominal pain, diarrhea or dysentery. • Following the prodromal illness, the sudden onset of- pallor, weakness, and lethargy • Significant dehydration or volume overload
  • 19. • Renal - Oliguria present in early stages /masked by ongoing diarrhea - Hematuria and hypertension are common - Renal insufficiency can be mild to severe oliguric or anuric renal failure. - life-threatening hyperkalemia(renal failure+severe hemolysis) - Severe acute kidney injury requiring dialysis develops in about 50% of patients with STEC-HUS. - The duration of the dialysis requirement is usually about 2 wk.
  • 20. • Cardiac - heart failure(Volume overload, hypertension, and severe anemia ) - Direct cardiac involvement is rare - pericarditis, myocardial dysfunction, or arrhythmias can occur without predisposing features of hypertension, volume overload, or electrolyte abnormalities.
  • 21. • CNS- mild manifestations - irritability, lethargy, or nonspecific encephalopathic features. • Severe CNS involvement- ≤ 20% of cases. - Seizures and significant encephalopathy resulting from focal ischemia secondary to microvascular CNS thrombosis • Hypertension encephalopathy and seizures. • Intestinal complications are variable - include severe inflammatory colitis, ischemic enteritis, bowel perforation, intussusception, and pancreatitis. • hematological - petechiae, significant or severe bleeding is rare despite very low platelet counts
  • 22. CLINICAL FEATURES.. • pneumococci-associated HUS- pt will be ill with pneumonia, empyema, and bacteremia when they develop HUS • genetic forms of HUS – insidious, triggered by a variety of illnesses, including mild, nonspecific gastroenteritis or respiratory tract infections.
  • 23. CLINICAL FEATURES.. • Cobalamin deficiency-associated HUS c/f • Feeding difficulties, seizures ,abnormal muscle tone, developmental delay and megaloblastic anemia are common; • Rarely- HUS have an indolent presentation- with AKI and systemic hypertension without thrombocytopenia or microangiopathic hemolysis.
  • 24. DIAGNOSIS OF HUS (i) microangiopathic hemolysis characterized by - anemia -(hemoglobin <10 g/dL) - fragmented red cells on peripheral smear (schistocytes ≥2%), - High lactate dehydrogenase >450 IU/l (increased breakdown and turnover of RBC’S) or - undetectable haptoglobin(binding with released hemoglobin. ) (ii) thrombocytopenia (platelets <150,000/μL) (iii) AKI- (rise in creatinine by 50% over baseline). .
  • 26. • The degree of leukocytosis -poor outcome • Reticulocyte levels are high. • The degree of renal involvement - increase in blood urea, creatinine, potassium and phosphate. • liver transaminases, pancreatic enzymes and glucose levels may be affected. • Urinalysis reveals- hemoglobinuria, hematuria and proteinuria.
  • 27. SUSPECTED SHIGA TOXIN ASSOCIATED HUS: DIAGNOSIS confirmed by positive stool culture and either of the following (i) Detection of virulence genes on fecal extracts or cultures (stx1, stx2, and eae gene by PCR) (ii) Free fecal Shiga toxin (detected on tissue culture or immunoassay) (iii) The presence of serum IgM antibodies against specific E. coli lipopolysaccharide -evidence for recent STEC infection (by ELISA, passive hemagglutination assay)
  • 28. DIAGNOSIS OF PNEUMOCOCCAL HUS • positive direct Coombs’ test without features of DIC • confirmed by either: (i) S. pneumoniae isolation - bacterial culture - detection of pneumococcal antigen by PCR or ELISA in appropriate body fluids (sputum/CSF/blood/pus) or - positive peanut lectin (Arachis hypogaea) agglutination assay
  • 29. COBALAMIN DEFICIENCY-ASSOCIATED HUS • screening for cobalamin C (cblC) deficiency by estimating total homocysteine levels • Probable cblC deficiency-related HUS- elevated plasma total homocysteine level (> 50–100 μM/l by chromatography, immunoassay) with normal levels of vitamin B12 and folate. • Confirmed cblC deficiency-related HUS- Homozygous or compound heterozygous mutation in the MMACHC gene in a patient with probable cblC deficiency.
  • 30. Rule-out • Disseminated intravascular coagulation (DIC) - prolonged prothrombin time or activated partial thromboplastin time, low fibrinogen, elevated D-dimer and soluble fibrin monomers. • Thrombotic thrombocytopenic purpura (TTP) -rare in childhood -persistent thrombocytopenia (<30,000/μL) and mild/no AKI is suggestive • Infections that mimic/trigger HUS, e.g., malaria, leptospirosis, dengue, rickettsia and H1N1 infection should be excluded, if clinically suspected. • Blood samples should be stored and later processed for ADAMTS13 activity, if etiology of microangiopathic anemia is unclear.
  • 31. EVALUATION OF ATYPICAL HUS Complement C3 - A low C3 level is not specific for aHUS, nor does it correlate with severity of disease test for anti-factor H (FH) antibodies – ELIZA flow cytometry for expression of membrane cofactor protein (MCP, CD46) on neutrophils Gene sequencing:of CFH, CFI, CFB, C3, CD46, THBD, and DGKE. • Blood specimens for C3 and anti-FH antibodies should be drawn prior to instituting therapy.
  • 32. Genetic screening is advised (i) early age of onset (ii) relapsing course, (iii) family history of HUS, (iv) illness that is refractory to therapy with PEX, and (v) prior to renal transplantation.
  • 33. RENAL BIOPSY • Renal biopsy is not essential for diagnosis • cannot be performed in the acute stage due to thrombocytopenia. • Indicated - partial forms where the diagnosis is in doubt, or in recurrent or severe disease, to confirm the diagnosis before starting aggressive therapies. The pathognomic finding of TMA is common to all types.
  • 34. RENAL BIOPSY.  Thus - predominantly fibrin thrombi are found in glomerular capillaries. aHUS- the thrombi are made up of a combination of fibrin, platelet and VWF clumps that involve larger renal and interlobular arterioles, thus causing ischemia and inflammation of larger volumes of renal parenchyma - Glomerular capillary wall thickening, occlusion or narrowing of capillary lumens, inflammation and necrosis of endothelial cells and their detachment from the basement membrane may be observed. - Tubular epithelial injury, mesangial expansion and mesangiolysis may also occur • Cortical necrosis is present in severe cases, and indicates a poor outcome
  • 35. A) Occluded afferent arteriole with ischemic changes in the accompanying glomerulus B) Glomerulus showing mesangiolysis and ectatic dilatation of glomerular capillaries (silver methenamine C) (C) Necrotizing vascular lesions of the afferent and efferent arterioles D) (D) Fibrin rich thrombus occluding the lumen of a small artery with ischemic changes in adjacent glomerulus
  • 37. DFFERNTIAL DIAGNOSIS • Acute abdomen • Acute gastroenteritis • Appendicitis • Colitis • Disseminated intravascular coagulation • Inflammatory bowel disease • Lupus • Thrombotic thrombocytopenia
  • 39. Supportive Therapy • In all patients, supportive treatment is primary. • Close clinical monitoring of : -Fluid status -Blood pressure -Neurological -Ventilatory parameters • Blood levels of glucose, electrolytes, creatinine and hemogram need frequent monitoring
  • 40. MANAGEMENT.. • Dialysis - early institution- if the patient - significantly oliguric or anuric, with hyperkalemia. • The duration of the dialysis requirement is usually about 2 wk. • Red cell transfusions required because hemolysis can be brisk and recurrent until the active phase of the disease has resolved. -In pneumococci associated HUS- administer washed red cells to be given Platelets should not be administered ( Rapidly consumed by the active coagulation ,worsen the clinical course)
  • 41. • Anticoagulation, antiplatelet, and fibrinolytic therapies are specifically contraindicated- increase the risk of serious hemorrhage. • Antibiotic therapy to clear enteric toxigenic organisms (STEC) can result in increased toxin release, potentially exacerbating the disease, and therefore is not recommended. - Indicated in pneumococcal infection. • Plasma infusion or plasmapheresis- patients suffering from severe manifestations of HUS with serious CNS involvement. • contraindicated in pneumococcal associated HUS -exacerbate the disease
  • 42. MANAGEMENT- Atypical HUS: ECULIZUMAB • Across the developed world, eculizumab, is the standard of care for patients with aHUS. • FDA approved for the treatment of atypical HUS • Eculizumab is an anti-C5 antibody that inhibits complement activation, a pathway that contributes to active disease in atypical familial HUS.
  • 43. • recommended to give the meningococcal vaccine prior to giving eculizumab (if the patient has not been primarily immunized)- risk of meningococcal disease in patients with defects in terminal complement components • eculizumab is expensive and not available in India and developing countries.
  • 44. PLASMA EXCHANGE • In absence of anti-complement therapies, intensive PEX is less than ideal, but the only alternative. • PEX - (60- 75 mL/kg; fresh frozen plasma as exchange fluid) - appropriate for patients with suspected aHUS. • PEX is administered daily until hematological remission and tapered over 4-6 weeks. - (platelets >100,000/ μL, schistocytes <2%, LDH less than upper limit of normal for 2 consecutive days) • Maintenance therapy with plasma infusions is advised every 10-14 days for patients with mutations in complement genes, especially CFH and CFI.
  • 45. • Limited benefit of PEX in patients with: (i) microbiologically confirmed STEC-HUS, without cardiac or neurological involvement, (ii) infection-associated HUS or pathogenic variants in CD46 and DGKE.
  • 46. MANAGEMENT - ANTI-FH ANTIBODY ASSOCIATED AHUS: • Aim of therapy - anti-FH associated HUS is reduction of titers, PEX are most appropriate to achieve this goal. • Combination of PEX and immunosuppression was most useful. • Immunosuppression must not be used without confirming presence of anti-FH antibodies. • Therapy is initiated with prednisolone 1 mg/kg/day for 4 weeks, then alternate-day followed by tapering over 10- 12 months • Therapy includes cyclophosphamide (500 mg/m2 intravenously once in 4-weeks) for 5 doses • About 15- 30% patients relapse; Antibody titers should be sequentially measured, especially in the first 12-24 months of follow up. • Maintenance therapy with mycophenolate mofetil or azathioprine for 18-24 months, and tapering prednisolone further reduces the risk of relapses.
  • 48. Management - Miscellaneous • In infants with HUS associated with cobalamin abnormalities: Treatment with hydroxycobalamin, Oral betaine, Folic acid • Normalizes the metabolic abnormalities - prevent further episodes. • In patients with persistent ADAMTS13 antibodies and poor response to plasma exchange: • Immunosuppressive therapy with high dose - steroids/cyclophosphamide/cyclosporin/rituximab
  • 49. PROGNOSIS • With early recognition and intensive supportive care, the mortality rate for diarrhea-associated HUS is < 5% in most major medical centers. • Up to half of patients may require dialysis support during the acute phase of the disease. • Recovery of platelet counts usually occurs first, followed by renal recovery about 5 days later, and finally by resolution of anemia. • Surviving patients, 5% remain dependent on dialysis, and up to 30% are left with some degree of chronic renal insufficiency.
  • 50. • The prognosis for HUS not associated with diarrhea is more severe. • Pneumococci-associated HUS causes increased patient morbidity (>80% require dialysis), with the mortality rate reported as 20%. • familial, genetic forms of HUS can be insidiously progressive or relapsing diseases and have a poor prognosis
  • 52. REFERENCES • Guidelines on Hemolytic Uremic Syndrome by Indian Society of Pediatric Nephrology • Hemolytic uremic syndrome in a developing country: Consensus guidelines Pediatric Nephrology Arvind Bagga/Revised: 6 January 2019 • Bagga text book of paediatric nephrology • Nelson text book of paediatrics 21st edition